NM_000492.4:c.870-1113_870-1110delGAAT
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_000492.4(CFTR):c.870-1113_870-1110delGAAT variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000492.4 intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.870-1113_870-1110delGAAT | intron_variant | Intron 7 of 26 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:2Other:1
This sequence change falls in intron 7 of the CFTR gene. It does not directly change the encoded amino acid sequence of the CFTR protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with cystic fibrosis (PMID: 19759008, 21783433). ClinVar contains an entry for this variant (Variation ID: 54075). Studies have shown that this variant alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 19759008). For these reasons, this variant has been classified as Pathogenic. -
- -
The c.870-1110_870-1113delGAAT intronic variant, located in intron 7 of the CFTR gene, results from a deletion of 4 nucleotides within intron 7 of the CFTR gene. Two studies evaluating mRNA from patients' nasal epithelial cells revealed the inclusion of 97 base pairs of intron 7 sequence between exons 7 and 8 (Faà V et al. J. Biol. Chem., 2009 Oct;284:30024-31; Costa C et al. J. Cyst. Fibros., 2011 Dec;10:479-82). A minigene assay of wild-type and mutant constructs further demonstrated that this deletion abolished the binding site for hnRNPA2/B1 and created a binding site for SRp75 splicing factor (Faà V et al. J. Biol. Chem., 2009 Oct;284:30024-31). Multiple patients, mostly of Italian or French origin, have been described to be heterozygous for this alteration and a second pathogenic mutation; methods for phasing (cis vs. trans) were not described. Reported phenotypes and age at diagnosis have varied, but are most consistent with classic cystic fibrosis (Faà V et al. J. Biol. Chem., 2009 Oct;284:30024-31; Costa C et al. J. Cyst. Fibros., 2011 Dec;10:479-82). Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
- -
Cystic fibrosis;C5924204:CFTR-related disorder Pathogenic:1
when the variant is in trans with another CF-causing variation, can either result in CF or in a CFTR-RD -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at